Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third- line therapy in patients with platinum-refractory or -resistant ovarian cancer
Canfosfamide HCl (CAN) is a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and induces apoptosis. CAN is synergistic in vitro with car- boplatin, paclitaxel and anthracyclines.
